Read article—Tyler Curiel, a professor of medicine, talks about his study reporting that the blood-pressure medicine Telmisartan may enhance the efficacy of cancer treatments known as PARP inhibitors. "This study shows that a common, safe, tolerable, convenient, and inexpensive drug may significantly improve how well an important class of cancer therapies works," Curiel said.